Cessatech A/S Logo

Cessatech A/S

Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.

CESSA | SPGR

Overview

Corporate Details

ISIN(s):
DK0061411964
LEI:
549300WO5SKVXWPOXR16
Country:
Denmark
Address:
Kanonbådsvej 2, 1437 København K
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cessatech A/S is a pharmaceutical company specializing in the development and commercialization of evidence-based medicines for children. The company focuses on addressing unmet needs in pediatric care, particularly the treatment of acute pain. Its lead asset, CT001, is a non-invasive analgesic nasal spray for children aged 1-17 undergoing painful medical procedures. This product is designed as an alternative to traditional pain management solutions, such as intravenous injections, which can be distressing for young patients. Originating as a spinout project from Rigshospitalet, Cessatech's business model centers on developing drugs with a potentially shortened time-to-market. The management team has a proven track record in drug development, paediatric research, and global product launches.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cessatech A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cessatech A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cessatech A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA

Talk to a Data Expert

Have a question? We'll get back to you promptly.